Initial partial response and stable disease according to RECIST indicate similar survival for chemotherapeutical patients with advanced non-small cell lung cancer

Lijie He(First Hospital of China Medical University), Yunpeng Liu(Shenyang Institute of Automation), Songbai Li(Hubei Polytechnic University), Yuee Teng(First Hospital of China Medical University), Mingfang Zhao(First Hospital of China Medical University), Xuejun Hu(Zoucheng People's Hospital), Jingdong Zhang(Liaoning Cancer Hospital & Institute), Bo Jin, Yaling Gao(Fujian University of Technology), Ping Yu(First Hospital of China Medical University)
BMC Cancer
December 1, 2010
10.1186/1471-2407-10-681
Cited by 23

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
|The Lancet Oncology|2015|412